Compare Stocks: BCYC, CVAC, MLTX, and JANX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.65 -0.8%	$4.07	$3.61 ▼ $9.16	$255.47M	1.54	354,287 shs	240,419 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
JANX Janux Therapeutics	$16.59 -1.6%	$16.99	$12.12 ▼ $35.34	$1.01B	2.53	978,949 shs	2.45 million shs
MLTX MoonLake Immunotherapeutics	$12.39 +0.3%	$16.55	$5.95 ▼ $62.75	$1.05B	1.04	1.37 million shs	1.80 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-5.44%	-13.92%	-8.64%	-47.25%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
JANX Janux Therapeutics	0.00%	-2.98%	-3.99%	+16.67%	-29.28%
MLTX MoonLake Immunotherapeutics	0.00%	-0.96%	-21.93%	-35.50%	-75.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.65 -0.8%	$4.07	$3.61 ▼ $9.16	$255.47M	1.54	354,287 shs	240,419 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
JANX Janux Therapeutics	$16.59 -1.6%	$16.99	$12.12 ▼ $35.34	$1.01B	2.53	978,949 shs	2.45 million shs
MLTX MoonLake Immunotherapeutics	$12.39 +0.3%	$16.55	$5.95 ▼ $62.75	$1.05B	1.04	1.37 million shs	1.80 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-5.44%	-13.92%	-8.64%	-47.25%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
JANX Janux Therapeutics	0.00%	-2.98%	-3.99%	+16.67%	-29.28%
MLTX MoonLake Immunotherapeutics	0.00%	-0.96%	-21.93%	-35.50%	-75.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	279.65% Upside
CVAC CureVac	1.00	Sell	N/A	N/A
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	119.78% Upside
MLTX MoonLake Immunotherapeutics	2.44	Hold	$24.57	98.32% Upside

Current Analyst Ratings Breakdown

Latest BCYC, CVAC, MLTX, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	JANX Janux Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
8/7/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/7/2026	JANX Janux Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00
8/7/2026	JANX Janux Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $55.00
7/30/2026	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
7/20/2026	JANX Janux Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/20/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$72.86M	3.51	N/A	N/A	$8.79 per share	0.42
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
JANX Janux Therapeutics	$10M	101.43	N/A	N/A	$15.91 per share	1.04
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)

Latest BCYC, CVAC, MLTX, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	12.08	12.08
CVAC CureVac	0.03	3.70	3.69
JANX Janux Therapeutics	N/A	16.35	16.35
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
CVAC CureVac	17.26%
JANX Janux Therapeutics	75.39%
MLTX MoonLake Immunotherapeutics	93.85%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.00%
CVAC CureVac	2.15%
JANX Janux Therapeutics	7.90%
MLTX MoonLake Immunotherapeutics	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	288	69.99 million	54.60 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
JANX Janux Therapeutics	113	61.14 million	56.31 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable

BCYC, CVAC, MLTX, and JANX Headlines

Recent News About These Companies

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Upgraded by Wall Street Zen

September 19 at 1:13 AM | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Sell at Wall Street Zen

September 19 at 1:11 AM | marketbeat.com

111,590 Shares in MoonLake Immunotherapeutics $MLTX Purchased by Engineers Gate Manager LP

September 15, 2026 | marketbeat.com

MLTX stock on track for worst week since last fall as FDA filing date for skin disease drug draws near

September 11, 2026 | msn.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 7.7% - Time to Sell?

September 9, 2026 | marketbeat.com

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy

September 8, 2026 | seekingalpha.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Hold" by Brokerages

September 4, 2026 | marketbeat.com

MoonLake Immunotherapeutics (MLTX)

August 23, 2026 | finance.yahoo.com

Bank of America Corp DE Has $13.51 Million Stock Holdings in MoonLake Immunotherapeutics $MLTX

August 22, 2026 | marketbeat.com

MoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’

August 11, 2026 | msn.com

MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals

August 10, 2026 | finance.yahoo.com

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...

August 10, 2026 | markets.businessinsider.com

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

August 10, 2026 | benzinga.com

MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

August 10, 2026 | reuters.com

MoonLake announces positive Phase 3 psoriatic arthritis results

August 10, 2026 | tipranks.com

MoonLake reports positive Phase 3 PsA data and $537 million cash

August 10, 2026 | quiverquant.comQ

MoonLake Immunotherapeutics GAAP EPS of -$0.84

August 10, 2026 | seekingalpha.com

MLTX stock under pressure as investors await psoriatic arthritis trial data

August 3, 2026 | msn.com

Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 5.02%

August 3, 2026 | aaii.comA

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

July 31, 2026 | zacks.com

Kristian Reich Sells 1,100 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

July 30, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, CVAC, MLTX, and JANX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$3.65 -0.03 (-0.82%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.64 -0.02 (-0.41%)

As of 09/18/2026 07:30 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 09/18/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Janux Therapeutics NASDAQ:JANX

$16.59 -0.27 (-1.60%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$16.59 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

MoonLake Immunotherapeutics NASDAQ:MLTX

$12.39 +0.04 (+0.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.36 -0.03 (-0.20%)

As of 09/18/2026 07:53 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCYC, CVAC, MLTX, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCYC, CVAC, MLTX, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCYC, CVAC, MLTX, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, CVAC, MLTX, and JANX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

CureVac NASDAQ:CVAC

Janux Therapeutics NASDAQ:JANX

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCYC, CVAC, MLTX, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCYC, CVAC, MLTX, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCYC, CVAC, MLTX, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, CVAC, MLTX, and JANX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

CureVac NASDAQ:CVAC

Janux Therapeutics NASDAQ:JANX

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools